Aduro Biotech Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aduro Biotech in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Aduro Biotech stock.
View analyst ratings for Aduro Biotech or view top-rated stocks.

Wall Street analysts have given Aduro Biotech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aduro Biotech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Aduro Biotech, Inc. (NASDAQ:ADRO) released its quarterly earnings results on Monday, May, 4th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.05. The biotechnology company had revenue of $13.95 million for the quarter, compared to analyst estimates of $8.81 million. Aduro Biotech had a negative trailing twelve-month return on equity of 101.73% and a negative net margin of 230.92%.
View Aduro Biotech's earnings history.

2 brokers have issued twelve-month target prices for Aduro Biotech's stock. Their forecasts range from $3.75 to $3.75. On average, they anticipate Aduro Biotech's share price to reach $3.75 in the next twelve months.
View analysts' price targets for Aduro Biotech or view top-rated stocks among Wall Street analysts.

Some companies that are related to Aduro Biotech include Kiniksa Pharmaceuticals (KNSA), Amphastar Pharmaceuticals (AMPH), Constellation Pharmaceuticals (CNST), ESSA Pharma (EPIX), ORIC Pharmaceuticals (ORIC), Epizyme (EPZM), Syndax Pharmaceuticals (SNDX), Affimed (AFMD), Trillium Therapeutics (TRIL), G1 Therapeutics (GTHX), Dyne Therapeutics (DYN), Prothena (PRTA), Vectura Group (VEGPF), Merus (MRUS) and Dynavax Technologies (DVAX).
View all of ADRO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aduro Biotech investors own include Regulus Therapeutics (RGLS), Exact Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Nabriva Therapeutics (NBRV), Amarin (AMRN), Anavex Life Sciences (AVXL), Micron Technology (MU), VBI Vaccines (VBIV) and PTC Therapeutics (PTCT).

(ADRO) raised $119 million in an initial public offering on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Aduro Biotech trades on the NASDAQ under the ticker symbol "ADRO."

Aduro Biotech has a market capitalization of $0.00 and generates $17.26 million in revenue each year. The biotechnology company earns $-82,370,000.00 in net income (profit) each year or ($5.15) on an earnings per share basis.

Aduro Biotech employs 152 workers across the globe.

The official website for Aduro Biotech is www.aduro.com.

Aduro Biotech is headquartered at 740 HEINZ AVENUE, BERKELEY CA, 94710.

Aduro Biotech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at (206) 485-7051 or via email at [email protected]